ICON will be participating in ACOP 2025 in Aurora, Colorado, where we will introduce Yi Zhang, our new Scientific Director of PK in the Pharmacometrics Department. Yi brings extensive expertise in PK/PD modeling, disea...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Navigating, manufacturing, infrastructure and regulatory hurdles in CAR T-Cell therapy growth
Explore how industry leaders are overcoming manufacturing and regulatory hurdles to scale CAR-T cell therapies across Asia-Pacific.
-
ICON recognised as one of World's top companies for women
ICON have been included in Forbes' list of only 400 global companies. Based on a survey of approximately 120,000 women in more than 36 countries, positions were awarded to companies that have been identified as top performers in promoting gender equality and supporting women in the workplace.
-
Precision medicine meets machine learning: AI and oncology biomarkers
AI is redefining oncology biomarker discovery, unlocking new precision in patient selection and trial design. Explore how this evolving technology is shaping the future of cancer drug development.
-
Smarter starts, stronger trials: How data is driving faster site activation
Feasibility, site selection and study startup are among the most complex areas of clinical development, yet they remain stubbornly inefficient. ICON’s Brian Mallon explores how sponsors and CROs are leveraging AI, predictive analytics and integrated data environments for faster, more predictable trial delivery and stronger site partnerships. Read the full article.
-
Clinical trials - Keeping pace with shifting drug development paradigms for multi-indication therapies
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
-
Fights over Tylenol, SSRIs highlight the enduring lack of pregnant women in drug trials
Read the article to learn why the exclusion of pregnant women from clinical trials continues to fuel data gaps, misinformation, and missed opportunities for safer, more effective treatments.
-
Smarter strategies for systematic literature reviews
Conducting a high-quality, clinically relevant literature review can be challenging – it demands strategic thinking, methodological rigour and therapeutic expertise. ICON expert Rebecca Rozich explains why systematic literature reviews can be a powerful alternative to generating new data.
-
Beyond approval
In the October issue of PharmaTimes, Dr. Quintin van Wyk considers the importance of post-marketing pharmacovigilance, and explains how carefully applied automation and AI can strengthen adverse event reporting and causality assessment while keeping patient safety and regulatory compliance central.
-
Impact assessment is the first, critical step to updated ICH GCP compliance
ICH GCP E6(R3) is here. In the latest issue of PharmaTimes, ICON explores why a comprehensive impact assessment is the essential first step toward strategic compliance.
-
How cancer regulation is — and isn’t — changing at FDA: a BioCentury podcast
Dr. Liz O’Brien, Senior Director of Global Drug Development at ICON and former EMA regulator, joined the BioCentury This Week podcast to share insights on navigating FDA’s Project Optimus, the EMA’s Joint Clinical Assessment and highlight the key differences between the two regulatory regimes.
